Style | Citing Format |
---|---|
MLA | Nazmabadi R, et al.. "Dihydroartemisinin Enhances the Therapeutic Efficacy of Bh3 Mimetic Inhibitor in Acute Lymphoblastic Leukemia Cells Via Inhibition of Mcl-1." Asian Pacific Journal of Cancer Prevention, vol. 25, no. 1, 2024, pp. 325-332. |
APA | Nazmabadi R, Pooladi M, Amri J, Abbasi Y, Karami H, Darvish M (2024). Dihydroartemisinin Enhances the Therapeutic Efficacy of Bh3 Mimetic Inhibitor in Acute Lymphoblastic Leukemia Cells Via Inhibition of Mcl-1. Asian Pacific Journal of Cancer Prevention, 25(1), 325-332. |
Chicago | Nazmabadi R, Pooladi M, Amri J, Abbasi Y, Karami H, Darvish M. "Dihydroartemisinin Enhances the Therapeutic Efficacy of Bh3 Mimetic Inhibitor in Acute Lymphoblastic Leukemia Cells Via Inhibition of Mcl-1." Asian Pacific Journal of Cancer Prevention 25, no. 1 (2024): 325-332. |
Harvard | Nazmabadi R et al. (2024) 'Dihydroartemisinin Enhances the Therapeutic Efficacy of Bh3 Mimetic Inhibitor in Acute Lymphoblastic Leukemia Cells Via Inhibition of Mcl-1', Asian Pacific Journal of Cancer Prevention, 25(1), pp. 325-332. |
Vancouver | Nazmabadi R, Pooladi M, Amri J, Abbasi Y, Karami H, Darvish M. Dihydroartemisinin Enhances the Therapeutic Efficacy of Bh3 Mimetic Inhibitor in Acute Lymphoblastic Leukemia Cells Via Inhibition of Mcl-1. Asian Pacific Journal of Cancer Prevention. 2024;25(1):325-332. |
BibTex | @article{ author = {Nazmabadi R and Pooladi M and Amri J and Abbasi Y and Karami H and Darvish M}, title = {Dihydroartemisinin Enhances the Therapeutic Efficacy of Bh3 Mimetic Inhibitor in Acute Lymphoblastic Leukemia Cells Via Inhibition of Mcl-1}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {25}, number = {1}, pages = {325-332}, year = {2024} } |
RIS | TY - JOUR AU - Nazmabadi R AU - Pooladi M AU - Amri J AU - Abbasi Y AU - Karami H AU - Darvish M TI - Dihydroartemisinin Enhances the Therapeutic Efficacy of Bh3 Mimetic Inhibitor in Acute Lymphoblastic Leukemia Cells Via Inhibition of Mcl-1 JO - Asian Pacific Journal of Cancer Prevention VL - 25 IS - 1 SP - 325 EP - 332 PY - 2024 ER - |